Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cyclacel Pharmaceuticals Inc
Net Change in Cash
Cyclacel Pharmaceuticals Inc
Net Change in Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
Net Change in Cash
-$1.7m
|
CAGR 3-Years
51%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
13%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Change in Cash
-$295m
|
CAGR 3-Years
19%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Change in Cash
-$2.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Change in Cash
-$2.8B
|
CAGR 3-Years
-99%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Change in Cash
$515.6m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
19%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Change in Cash
$634.7m
|
CAGR 3-Years
42%
|
CAGR 5-Years
2%
|
CAGR 10-Years
15%
|
|
Cyclacel Pharmaceuticals Inc
Glance View
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Berkeley Heights, New Jersey. The firm is engaged in developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The firm is focused on the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient’s overall survival. The firm's pipeline includes Fadraciclib, CYC140 and Sapacitabine. The Fadraciclib is a cyclin dependent kinase (CDK) inhibitor selectively targeting Cyclin Dependent Kinase 2 (CDK2) and Cyclin-dependent kinase 9 (CDK9). The CYC140 is a novel, small molecule, selective and potent PLK-centric inhibitor. The firm's Sapacitabine (CYC682) is an orally available nucleoside analogue with a DNA damage response (DDR) mechanism.
See Also
What is Cyclacel Pharmaceuticals Inc's Net Change in Cash?
Net Change in Cash
-1.7m
USD
Based on the financial report for Jun 30, 2025, Cyclacel Pharmaceuticals Inc's Net Change in Cash amounts to -1.7m USD.
What is Cyclacel Pharmaceuticals Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 10Y
13%
Over the last year, the Net Change in Cash growth was 58%. The average annual Net Change in Cash growth rates for Cyclacel Pharmaceuticals Inc have been 51% over the past three years , and 13% over the past ten years .
